Passage BIO, Inc. business relationships
Companies named in Passage BIO, Inc.’s 10-K filed 2026-03-03, and public companies whose annual reports name Passage BIO, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.0 / 10
- AI naming
- <1 / 100 Top 19% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Passage BIO, Inc.’s annual report 4
“Denali Therapeutics Inc., in partnership with Takeda Pharmaceutical Company Limited, is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein.” SEC filing
“AviadoBio Ltd entered into an exclusive option and licensing agreement with Astellas Pharma Inc. in October 2024.” SEC filing
“Denali Therapeutics Inc., in partnership with Takeda Pharmaceutical Company Limited, is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein.” SEC filing
“AviadoBio Ltd entered into an exclusive option and licensing agreement with Astellas Pharma Inc. in October 2024.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.